Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALZN

Alzamend Neuro Inc

Oct 23 • 02:43PM ET

2.36

+0.02 0.85 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN LLY MRK ABBV AZN BMY BIIB REGN VRTX GILD

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.67	Insider Own	3.25%	Shs Outstand	3.14M	Perf Week	0.00%
Market Cap	7.41M	Forward P/E	-	EPS next Y	-3.19	Insider Trans	-89.87%	Shs Float	3.04M	Perf Month	-0.84%
Enterprise Value	1.79M	PEG	-	EPS next Q	-1.96	Inst Own	0.07%	Short Float	6.90%	Perf Quarter	-20.27%
Income	-6.83M	P/S	-	EPS this Y	50.75%	Inst Trans	-0.02%	Short Ratio	1.61	Perf Half Y	-62.57%
Sales	0.00M	P/B	1.39	EPS next Y	39.30%	ROA	-156.14%	Short Interest	0.21M	Perf YTD	-77.39%
Book/sh	1.70	P/C	1.32	EPS next 5Y	34.20%	ROE	-302.25%	52W High	15.30 -84.58%	Perf Year	-84.84%
Cash/sh	1.79	P/FCF	-	EPS past 3/5Y	60.75% 30.49%	ROIC	-127.88%	52W Low	2.06 14.56%	Perf 3Y	-99.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.04% 6.16%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	90.99%	Oper. Margin	-	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.21	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.03	EPS Q/Q	88.62%	SMA20	-0.59%	Beta	-0.28	Target Price	42.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-1.15%	Rel Volume	0.38	Prev Close	2.34
Employees	7	LT Debt/Eq	0.00	Earnings	Sep 16	SMA200	-54.16%	Avg Volume	130.51K	Price	2.36
IPO	Jun 15, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-14.18% -	Trades		Volume	41,091	Change	0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy	$8

Jul-28-25 08:00AM	Alzamend Neuro to Present at the 2025 Military Health System Research Symposium (GlobeNewswire) -6.42%
Jul-23-25 08:00AM	Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs (GlobeNewswire) -5.94%
Jun-16-25 08:00AM	Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule (GlobeNewswire)
May-29-25 08:00AM	Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) +63.86%
May-19-25 08:00AM	Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) +5.88%
08:00AM	Loading…
May-13-25 08:00AM	Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) -18.83%
07:30AM	EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants (Benzinga)
May-08-25 08:00AM	Alzamend Neuro Announces Reverse Stock Split (GlobeNewswire) -9.40%
May-07-25 08:00AM	Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital (GlobeNewswire) -6.22%
07:31AM	EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program (Benzinga)
Apr-08-25 09:55AM	Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks) -5.24%
Mar-28-25 10:42AM	Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? (Insider Monkey)
Mar-25-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital (GlobeNewswire)
Mar-18-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital (GlobeNewswire) +5.03%
Mar-11-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital (GlobeNewswire)
08:10AM	Loading…
Mar-04-25 08:10AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital (GlobeNewswire)
Feb-25-25 08:00AM	Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital (GlobeNewswire)
07:30AM	EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 (Benzinga)
Feb-19-25 08:00AM	Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital (Business Wire) -6.48%
07:30AM	EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels (Benzinga)
Jan-23-25 09:40AM	Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-15-25 08:00AM	Alzamend Neuro to Present at the Sequire Investor Summit (Business Wire)
Dec-18-24 08:00AM	Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo (Business Wire)
Dec-13-24 08:15AM	Alzamend Neuro says net cash gained by financing activity $8.3M (TipRanks)
Dec-12-24 08:00AM	Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs (Business Wire)
Nov-19-24 08:00AM	Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimers Transgenic Mice (Business Wire)
07:30AM	EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential (Benzinga)
Oct-16-24 08:00AM	Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
07:30AM	EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's (Benzinga)
Oct-15-24 08:00AM	Alzamend Neuro Regains Compliance with Nasdaq Listing Standards (Business Wire)
08:00AM	Loading…
Oct-10-24 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Groups Virtual Healthcare Conference (Business Wire)
Aug-26-24 08:00AM	Alzamend Neuro Issues Letter to Stockholders (Business Wire) -7.47%
Aug-19-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder (Business Wire) +186.78%
Aug-12-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder (Business Wire)
Aug-06-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder (Business Wire) -9.84%
05:32AM	Alzamend Neuro partners with Mass General for Alzheimers treatment trial (Clinical Trials Arena)
Aug-05-24 09:09AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimers Disease (Business Wire) -22.09%
07:30AM	EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study (Benzinga)
Jul-31-24 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
Jul-12-24 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire)
May-22-24 08:00AM	Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel (Business Wire)
May-14-24 08:00AM	Alzamend Neuro Announces Initial Closing of Private Placement (Business Wire) +18.81%
May-09-24 09:30AM	EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares (Benzinga) +11.74%
08:00AM	Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million (Business Wire)
May-07-24 08:00AM	Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program (Business Wire) -20.02%
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Mar-26-24 05:52AM	ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024 (InvestorPlace)
Dec-18-23 12:03PM	ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024 (InvestorPlace)
12:03PM	ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024 (InvestorPlace)
Dec-11-23 09:30AM	EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year (Benzinga) -6.54%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients (Business Wire)
Nov-20-23 08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients (Business Wire) -17.75%
Nov-16-23 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
Nov-13-23 08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire) -6.85%
Oct-30-23 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire) -24.62%
Oct-23-23 09:31AM	EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire)
Oct-02-23 09:30AM	EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder (Benzinga) -8.48%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Sep-22-23 08:00AM	Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement (Business Wire)
Aug-30-23 09:30AM	EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Jun-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study (Benzinga)
08:00AM	Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 (Business Wire)
Jun-13-23 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Groups Virtual Healthcare Conference (Business Wire)
May-24-23 08:00AM	3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024 (InvestorPlace) +10.30%
May-11-23 12:38PM	3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year (InvestorPlace)
Apr-04-23 06:30AM	Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Apr-03-23 09:35AM	KILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) +15.29%
09:34AM	EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine (Benzinga)
08:50AM	Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Mar-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial (Benzinga)
08:00AM	Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Mar-17-23 07:09AM	We Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully (Simply Wall St.) -12.36%
Mar-16-23 08:00AM	Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update (Business Wire)
Jan-26-23 08:00AM	Alzamend Neuro to Present at Sequire Biotechnology Conference (Business Wire) +9.48%
Jan-04-23 08:00AM	Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial (Business Wire)
Dec-28-22 08:00AM	Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) -11.31%
07:31AM	EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia (Benzinga)
Dec-13-22 03:52PM	10 Biotech Stocks With The Biggest Upside (Insider Monkey)
Nov-22-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc. (ACCESSWIRE) +10.62%
Nov-15-22 08:00AM	Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline (Business Wire)
Oct-31-22 08:00AM	Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Oct-11-22 10:03AM	Alzamend Neuro, Inc.'s (NASDAQ:ALZN) top owners are individual investors with 46% stake, while 21% is held by private companies (Simply Wall St.) -11.19%
Oct-05-22 12:45PM	Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial (Benzinga) +7.25%
08:00AM	Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimers Subjects (Business Wire)
Sep-29-22 12:29PM	Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Sep-22-22 08:00AM	Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement (Business Wire) -7.63%
Aug-25-22 07:13AM	We Think Alzamend Neuro (NASDAQ:ALZN) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-24-22 08:41AM	6 Penny Stocks With 1,000% Upside Potential (InvestorPlace)
Jul-18-22 10:42AM	Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate (Benzinga)
08:00AM	Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Business Wire)
Jun-20-22 09:22AM	10 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
Jun-03-22 08:00AM	Alzamend Neuro to Present at the 12th Annual LD Micro Invitational (Business Wire)
May-17-22 08:00AM	Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Business Wire) +7.25%
May-06-22 09:02AM	10 Biotech Penny Stocks Redditors Love (Insider Monkey) -6.74%
May-05-22 08:00AM	Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
May-04-22 06:25AM	What Kind Of Investors Own Most Of Alzamend Neuro, Inc. (NASDAQ:ALZN)? (Simply Wall St.)
Apr-28-22 06:30AM	BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AULT MILTON C III	Director	Oct 08 '25	Sale	2.44	101,394	247,158	28,657	Oct 10 04:30 PM
AULT MILTON C III	Director	Oct 09 '25	Sale	2.32	20,397	47,390	8,260	Oct 10 04:30 PM
AULT MILTON C III	Director	Oct 06 '25	Sale	2.45	82,033	201,268	26,227	Oct 08 06:50 AM
AULT MILTON C III	Director	Oct 07 '25	Sale	2.49	57,379	142,954	68,848	Oct 08 06:50 AM
AULT MILTON C III	Director	Oct 03 '25	Sale	2.44	65,903	160,889	8,260	Oct 03 09:35 PM
AULT MILTON C III	Director	Oct 01 '25	Sale	2.35	36,777	86,378	94,849	Oct 03 09:35 PM
AULT MILTON C III	Director	Oct 02 '25	Sale	2.39	20,686	49,522	74,163	Oct 03 09:35 PM
AULT MILTON C III	Director	Sep 29 '25	Sale	2.31	38,324	88,490	35,192	Sep 30 07:15 PM
AULT MILTON C III	Director	Sep 26 '25	Sale	2.31	37,738	87,345	73,516	Sep 30 07:15 PM
AULT MILTON C III	Director	Sep 30 '25	Sale	2.33	3,566	8,321	31,626	Sep 30 07:15 PM
AULT MILTON C III	Director	Sep 23 '25	Sale	2.38	43,238	102,721	65,022	Sep 25 08:59 PM
AULT MILTON C III	Director	Sep 24 '25	Sale	2.31	39,140	90,374	25,882	Sep 25 08:59 PM
AULT MILTON C III	Director	Sep 25 '25	Sale	2.31	14,628	33,829	11,254	Sep 25 08:59 PM
AULT MILTON C III	Director	Sep 19 '25	Sale	2.35	77,009	180,856	8,260	Sep 23 04:30 PM
AULT MILTON C III	Director	Sep 18 '25	Sale	2.47	20,870	51,493	85,269	Sep 19 04:50 PM
AULT MILTON C III	Director	Sep 17 '25	Sale	2.45	2,121	5,204	106,139	Sep 19 04:50 PM
AULT MILTON C III	Director	Jul 31 '25	Sale	2.22	100,000	221,550	8,260	Aug 01 04:30 PM
AULT MILTON C III	Director	Jul 30 '25	Sale	2.51	29,449	73,982	108,260	Aug 01 04:30 PM
AULT MILTON C III	Director	Jul 25 '25	Sale	2.90	36,532	105,855	46,020	Jul 29 04:55 PM
AULT MILTON C III	Director	Jul 28 '25	Sale	2.68	8,311	22,314	37,709	Jul 29 04:55 PM
AULT MILTON C III	Director	Jul 23 '25	Sale	2.95	59,516	175,584	92,173	Jul 25 08:00 PM
AULT MILTON C III	Director	Jul 24 '25	Sale	2.93	9,621	28,237	82,552	Jul 25 08:00 PM
AULT MILTON C III	Director	May 12 '25	Sale	5.06	1,213	6,138	8,260	May 14 05:00 PM
AULT MILTON C III	Director	May 12 '25	Sale	5.28	11	58	1,843	May 14 05:00 PM
Hyperscale Data, Inc.	10% Owner	May 12 '25	Proposed Sale	0.54	516,090	278,689		May 09 07:49 PM
Horne William B.	Director	Mar 26 '25	Buy	0.99	3,334	3,285	30,000	Mar 27 07:30 AM
AULT MILTON C III	Director	Mar 21 '25	Buy	1.02	2,905	2,969	85,273	Mar 25 04:30 PM
Katzoff David J	Chief Financial Officer	Mar 21 '25	Buy	1.01	5,000	5,048	5,540	Mar 24 07:30 AM
Horne William B.	Director	Mar 20 '25	Buy	0.98	5,000	4,892	26,666	Mar 20 04:30 PM
Horne William B.	Director	Mar 18 '25	Option Exercise	0.06	10,000	600	16,666	Mar 19 04:30 PM
Horne William B.	Director	Mar 18 '25	Buy	0.97	5,000	4,852	21,666	Mar 19 04:30 PM
AULT MILTON C III	Director	Mar 18 '25	Buy	0.96	5,000	4,810	82,368	Mar 18 07:12 PM
AULT MILTON C III	Director	Mar 12 '25	Buy	0.68	100	68	77,368	Mar 14 05:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALZN

Alzamend Neuro Inc

Upgrade your FINVIZ experience